BPT Crunch

Companies on the Cutting Edge of Healthcare Innovations

back to Marketplace

Aptose Biosciences

Aptose Biosciences logo

Founded
2014
Geography
United States of America based

Aptose Biosciences is a science-driven clinical-stage biotechnology company developing first-in-class targeted agents to address unmet clinical need in multiple hematologic malignancies.

Technologies

Antisense Oligonucleotides  


Posts Mentioning This Company

R&D Platform

CG-806, our oral mutation-agnostic FLT3/BTK inhibitor, is being developed for the treatment of patients with certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain non-Hodgkin’s lymphomas (NHL) who are resistant or intolerant to conventional treatments.

CG-806 is also being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML), including the emerging populations resistant to approved targeted therapies.

APTO-253, our first-in-class MYC Inhibitor, is being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).


Pipelines

No pipelines published yet

Products

 

Services

No services posted yet